Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

John D. Imig, Ahmed Abdelrazik Elmarakby, Kasem Nithipatikom, Shouzou Wei, Jorge H. Capdevila, Venugopal Raju Tuniki, Bhavani Sangras, Siddam Anjaiah, Vijaya L. Manthati, D. Sudarshan Reddy, John R. Falck

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Epoxyeicosatrienoic acids (EETs) contribute importantly to the regulation of vascular tone and blood pressure control. The purpose of this study was to develop stable EET analogs and test their in vivo blood pressure lowering effects in hypertensive rats. Using the pharmacophoric moiety of EETs, ether EET analogs were designed with improved solubility and resistance to auto-oxidation and metabolism by soluble epoxide hydrolase. Ether EET analogs were chosen based on their ability to dilate afferent arterioles and subsequently tested for blood pressure lowering effects in rodent models of hypertension. Initially, 11,12-ether-EET-8-ZE failed to lower blood pressure in angiotensin hypertension or spontaneously hypertensive rats (SHR). Esterification of the carboxylic group of 11,12-ether-EET-8-ZE prevented blood pressure increase in SHR when injected at 2 mg/day for 12 days (MAP Δ change at day 8 of injection was -0.3 ± 2 for treated and 12 ± 1 mmHg for control SHR). Amidation of the carboxylic group with aspartic acid produced another EET analog (NUDSA) with a blood pressure lowering effect when injected at 3 mg/day in SHR for 5 days. Amidation of the carboxylic group with lysine amino acid produced another analog with minimal blood pressure lowering effect. These data suggest that esterification of the carboxylic group of 11,12-ether-EET-8-ZE produced the most effective ether-EET analog in lowering blood pressure in SHR and provide the first evidence to support the use of EET analogs in treatment of cardiovascular diseases.

Original languageEnglish (US)
Article numberArtilce 157
JournalFrontiers in Physiology
Volume1 DEC
DOIs
StatePublished - Dec 1 2010

Fingerprint

Antihypertensive Agents
Ether
Blood Pressure
Inbred SHR Rats
Acids
Esterification
Hypertension
Epoxide Hydrolases
Angiotensins
Arterioles
Aspartic Acid
Solubility
Lysine
Blood Vessels
Rodentia
Cardiovascular Diseases
Amino Acids
Injections
11,12-epoxy-5,8,14-eicosatrienoic acid

Keywords

  • Afferent arteriole
  • Blood pressure
  • Epoxyeicosanoids
  • Hypertension
  • Vasodilation

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Imig, J. D., Elmarakby, A. A., Nithipatikom, K., Wei, S., Capdevila, J. H., Tuniki, V. R., ... Falck, J. R. (2010). Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. Frontiers in Physiology, 1 DEC, [Artilce 157]. https://doi.org/10.3389/fphys.2010.00157

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. / Imig, John D.; Elmarakby, Ahmed Abdelrazik; Nithipatikom, Kasem; Wei, Shouzou; Capdevila, Jorge H.; Tuniki, Venugopal Raju; Sangras, Bhavani; Anjaiah, Siddam; Manthati, Vijaya L.; Reddy, D. Sudarshan; Falck, John R.

In: Frontiers in Physiology, Vol. 1 DEC, Artilce 157, 01.12.2010.

Research output: Contribution to journalArticle

Imig, JD, Elmarakby, AA, Nithipatikom, K, Wei, S, Capdevila, JH, Tuniki, VR, Sangras, B, Anjaiah, S, Manthati, VL, Reddy, DS & Falck, JR 2010, 'Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions', Frontiers in Physiology, vol. 1 DEC, Artilce 157. https://doi.org/10.3389/fphys.2010.00157
Imig, John D. ; Elmarakby, Ahmed Abdelrazik ; Nithipatikom, Kasem ; Wei, Shouzou ; Capdevila, Jorge H. ; Tuniki, Venugopal Raju ; Sangras, Bhavani ; Anjaiah, Siddam ; Manthati, Vijaya L. ; Reddy, D. Sudarshan ; Falck, John R. / Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions. In: Frontiers in Physiology. 2010 ; Vol. 1 DEC.
@article{5ddd55a33e85428db775909b8cb56e79,
title = "Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions",
abstract = "Epoxyeicosatrienoic acids (EETs) contribute importantly to the regulation of vascular tone and blood pressure control. The purpose of this study was to develop stable EET analogs and test their in vivo blood pressure lowering effects in hypertensive rats. Using the pharmacophoric moiety of EETs, ether EET analogs were designed with improved solubility and resistance to auto-oxidation and metabolism by soluble epoxide hydrolase. Ether EET analogs were chosen based on their ability to dilate afferent arterioles and subsequently tested for blood pressure lowering effects in rodent models of hypertension. Initially, 11,12-ether-EET-8-ZE failed to lower blood pressure in angiotensin hypertension or spontaneously hypertensive rats (SHR). Esterification of the carboxylic group of 11,12-ether-EET-8-ZE prevented blood pressure increase in SHR when injected at 2 mg/day for 12 days (MAP Δ change at day 8 of injection was -0.3 ± 2 for treated and 12 ± 1 mmHg for control SHR). Amidation of the carboxylic group with aspartic acid produced another EET analog (NUDSA) with a blood pressure lowering effect when injected at 3 mg/day in SHR for 5 days. Amidation of the carboxylic group with lysine amino acid produced another analog with minimal blood pressure lowering effect. These data suggest that esterification of the carboxylic group of 11,12-ether-EET-8-ZE produced the most effective ether-EET analog in lowering blood pressure in SHR and provide the first evidence to support the use of EET analogs in treatment of cardiovascular diseases.",
keywords = "Afferent arteriole, Blood pressure, Epoxyeicosanoids, Hypertension, Vasodilation",
author = "Imig, {John D.} and Elmarakby, {Ahmed Abdelrazik} and Kasem Nithipatikom and Shouzou Wei and Capdevila, {Jorge H.} and Tuniki, {Venugopal Raju} and Bhavani Sangras and Siddam Anjaiah and Manthati, {Vijaya L.} and Reddy, {D. Sudarshan} and Falck, {John R.}",
year = "2010",
month = "12",
day = "1",
doi = "10.3389/fphys.2010.00157",
language = "English (US)",
volume = "1 DEC",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

AU - Imig, John D.

AU - Elmarakby, Ahmed Abdelrazik

AU - Nithipatikom, Kasem

AU - Wei, Shouzou

AU - Capdevila, Jorge H.

AU - Tuniki, Venugopal Raju

AU - Sangras, Bhavani

AU - Anjaiah, Siddam

AU - Manthati, Vijaya L.

AU - Reddy, D. Sudarshan

AU - Falck, John R.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Epoxyeicosatrienoic acids (EETs) contribute importantly to the regulation of vascular tone and blood pressure control. The purpose of this study was to develop stable EET analogs and test their in vivo blood pressure lowering effects in hypertensive rats. Using the pharmacophoric moiety of EETs, ether EET analogs were designed with improved solubility and resistance to auto-oxidation and metabolism by soluble epoxide hydrolase. Ether EET analogs were chosen based on their ability to dilate afferent arterioles and subsequently tested for blood pressure lowering effects in rodent models of hypertension. Initially, 11,12-ether-EET-8-ZE failed to lower blood pressure in angiotensin hypertension or spontaneously hypertensive rats (SHR). Esterification of the carboxylic group of 11,12-ether-EET-8-ZE prevented blood pressure increase in SHR when injected at 2 mg/day for 12 days (MAP Δ change at day 8 of injection was -0.3 ± 2 for treated and 12 ± 1 mmHg for control SHR). Amidation of the carboxylic group with aspartic acid produced another EET analog (NUDSA) with a blood pressure lowering effect when injected at 3 mg/day in SHR for 5 days. Amidation of the carboxylic group with lysine amino acid produced another analog with minimal blood pressure lowering effect. These data suggest that esterification of the carboxylic group of 11,12-ether-EET-8-ZE produced the most effective ether-EET analog in lowering blood pressure in SHR and provide the first evidence to support the use of EET analogs in treatment of cardiovascular diseases.

AB - Epoxyeicosatrienoic acids (EETs) contribute importantly to the regulation of vascular tone and blood pressure control. The purpose of this study was to develop stable EET analogs and test their in vivo blood pressure lowering effects in hypertensive rats. Using the pharmacophoric moiety of EETs, ether EET analogs were designed with improved solubility and resistance to auto-oxidation and metabolism by soluble epoxide hydrolase. Ether EET analogs were chosen based on their ability to dilate afferent arterioles and subsequently tested for blood pressure lowering effects in rodent models of hypertension. Initially, 11,12-ether-EET-8-ZE failed to lower blood pressure in angiotensin hypertension or spontaneously hypertensive rats (SHR). Esterification of the carboxylic group of 11,12-ether-EET-8-ZE prevented blood pressure increase in SHR when injected at 2 mg/day for 12 days (MAP Δ change at day 8 of injection was -0.3 ± 2 for treated and 12 ± 1 mmHg for control SHR). Amidation of the carboxylic group with aspartic acid produced another EET analog (NUDSA) with a blood pressure lowering effect when injected at 3 mg/day in SHR for 5 days. Amidation of the carboxylic group with lysine amino acid produced another analog with minimal blood pressure lowering effect. These data suggest that esterification of the carboxylic group of 11,12-ether-EET-8-ZE produced the most effective ether-EET analog in lowering blood pressure in SHR and provide the first evidence to support the use of EET analogs in treatment of cardiovascular diseases.

KW - Afferent arteriole

KW - Blood pressure

KW - Epoxyeicosanoids

KW - Hypertension

KW - Vasodilation

UR - http://www.scopus.com/inward/record.url?scp=84862963354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862963354&partnerID=8YFLogxK

U2 - 10.3389/fphys.2010.00157

DO - 10.3389/fphys.2010.00157

M3 - Article

VL - 1 DEC

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - Artilce 157

ER -